公开(公告)号：US20190263914A1

公开(公告)日：2019-08-29

申请号：US16210480

申请日：2018-12-05

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Jennifer Brogdon ,  Boris Engels ,  David Jonathan Glass ,  Brian Granda ,  John Hastewell ,  Andreas Loew ,  Joan Mannick ,  Michael C. Milone ,  Leon Murphy ,  William Raj Sellers ,  Huijuan Song ,  Brian Edward Vash ,  Jan Weiler ,  Qilong Wu ,  Li Zhou

IPC: C07K16/28 ,  A61K31/436 ,  C07K14/725 ,  C07K14/705 ,  C07K14/74 ,  C12N9/90 ,  A61K35/17 ,  C07K14/71 ,  C12N9/12

Abstract: Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.

公开(公告)号：US20240317850A1

公开(公告)日：2024-09-26

申请号：US18624860

申请日：2024-04-02

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Gregory Beatty ,  Boris Engels ,  Neeraja Idamakanti ,  Carl H. June ,  Andreas Loew ,  Michael C. Milone ,  Huijuan Song ,  Enxiu Wang ,  Qilong Wu

IPC: C07K16/28 ,  A61K35/17 ,  C07K14/705 ,  C07K14/725 ,  C07K14/735 ,  C07K14/74 ,  C07K16/30 ,  C12N5/0783

CPC classification number: C07K16/28 ,  A61K35/17 ,  C07K14/705 ,  C07K14/70503 ,  C07K14/7051 ,  C07K14/70535 ,  C07K14/70539 ,  C07K14/7056 ,  C07K14/70596 ,  C07K16/30 ,  C12N5/0636 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/74 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/70 ,  C07K2319/74 ,  C12N2510/00

Abstract: The present invention provides compositions and methods for regulating the specificity and activity of immune effector cells for use in immunotherapy. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “NKR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).

公开(公告)号：US20240294662A1

公开(公告)日：2024-09-05

申请号：US18647183

申请日：2024-04-26

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Gregory Beatty ,  Boris Engels ,  Neeraja Idamakanti ,  Carl H. June ,  Andreas Loew ,  Huijuan Song ,  Qilong Wu

IPC: C07K16/30 ,  A61K31/436 ,  A61K38/00 ,  A61K38/17 ,  A61K39/00 ,  A61K39/395 ,  A61K48/00 ,  C07K14/705 ,  C07K14/715 ,  C07K14/725 ,  C12N5/0783 ,  C12N15/85 ,  C12N15/86

CPC classification number: C07K16/30 ,  A61K31/436 ,  A61K38/1774 ,  A61K38/1793 ,  A61K39/001168 ,  A61K39/39558 ,  A61K48/0058 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/7151 ,  C07K16/303 ,  C07K16/3061 ,  C07K16/3069 ,  C12N5/0638 ,  C12N15/85 ,  C12N15/86 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/5158 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/74 ,  C12N2740/15041

Abstract: Provided are compositions and methods for treating diseases associated with expression of mesothelin. Also provided are a chimeric antigen receptor (CAR) specific to mesothelin, vectors encoding the same, and recombinant T cells comprising the mesothelin CAR. Further provided are methods of administering a genetically modified T cell expressing a CAR that comprises a mesothelin binding domain.

公开(公告)号：US11872249B2

公开(公告)日：2024-01-16

申请号：US17246351

申请日：2021-04-30

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Barbara Brannetti ,  Jennifer Brogdon ,  Boris Engels ,  Brian Walter Granda ,  Lu Huang ,  Ming Lei ,  Na Li ,  Jimin Zhang ,  Carla Patricia Pinto Guimaraes ,  Saar Gill ,  Marco Ruella ,  Regina M. Young

IPC: C07K16/28 ,  A61P35/00 ,  A61K38/17 ,  A61K39/00 ,  A61K35/17 ,  C12N15/85

CPC classification number: A61K35/17 ,  A61K38/1774 ,  A61P35/00 ,  C07K16/2803 ,  C07K16/2887 ,  C07K16/2896 ,  C12N15/85 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2319/03 ,  C07K2319/33

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.

公开(公告)号：US20230026049A1

公开(公告)日：2023-01-26

申请号：US17661207

申请日：2022-04-28

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Jennifer Brogdon ,  Boris Engels ,  David Jonathan Glass ,  Brian Granda ,  John Hastewell ,  Andreas Loew ,  Joan Mannick ,  Michael C. Milone ,  Leon Murphy ,  William Raj Sellers ,  Huijuan Song ,  Brian Edward Vash ,  Jan Weiler ,  Qilong Wu ,  Li Zhou

IPC: C07K16/28 ,  C07K14/725 ,  C07K14/705 ,  C07K14/74 ,  C12N9/90 ,  C12N9/12 ,  C07K14/71 ,  A61K31/436 ,  A61K35/17

Abstract: Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.

公开(公告)号：US20230000964A1

公开(公告)日：2023-01-05

申请号：US17811606

申请日：2022-07-11

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania ,  Dana-Farber Cancer Institute, Inc. ,  President and Fellows of Harvard College

Inventor： Jennifer Brogdon ,  Hwai Wen Chang ,  Boris Engels ,  Gordon James Freeman ,  Gerhard Johann Frey ,  Jennifer Marie Mataraza ,  Reshma Singh ,  Arlene Helen Sharpe

IPC: A61K39/00 ,  A61P35/00 ,  A61K39/395 ,  A61K45/06

Abstract: Provided are compositions and methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.

公开(公告)号：US20200371091A1

公开(公告)日：2020-11-26

申请号：US16768260

申请日：2018-11-30

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Iulian Pruteanu-Malinici ,  Keith Mansfield ,  Boris Engels ,  Jan J. Melenhorst ,  Adam David Cohen ,  Edward A. Stadtmauer ,  Alfred Garfall ,  Michael C. Milone ,  Joseph A. Fraietta

IPC: G01N33/50 ,  A61K35/17 ,  A61P35/02 ,  A61K45/06 ,  A61K39/395 ,  C07K16/28 ,  C07K16/24

Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to a method of administering a BCMA-targeting chimeric antigen receptor (CAR) therapy and an additional therapeutic agent.

公开(公告)号：US12186278B2

公开(公告)日：2025-01-07

申请号：US17811606

申请日：2022-07-11

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania ,  Dana-Farber Cancer Institute, Inc. ,  President and Fellows of Harvard College

Inventor： Jennifer Brogdon ,  Hwai Wen Chang ,  Boris Engels ,  Gordon James Freeman ,  Gerhard Johann Frey ,  Jennifer Marie Mataraza ,  Reshma Singh ,  Arlene Helen Sharpe

IPC: C07K16/00 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00

Abstract: Provided are compositions and methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.

公开(公告)号：US20240252538A1

公开(公告)日：2024-08-01

申请号：US18529915

申请日：2023-12-05

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Barbara Brannetti ,  Jennifer Brogdon ,  Boris Engels ,  Brian Walter Granda ,  Lu Huang ,  Ming Lei ,  Na Li ,  Jimin Zhang ,  Carla Patricia Pinto Guimaraes ,  Saar Gill ,  Marco Ruella ,  Regina M. Young

IPC: A61K35/17 ,  A61K38/17 ,  A61P35/00 ,  C07K16/28 ,  C12N15/85 ,  A61K39/00

CPC classification number: A61K35/17 ,  A61K38/1774 ,  A61P35/00 ,  C07K16/2803 ,  C07K16/2887 ,  C07K16/2896 ,  C12N15/85 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2319/03 ,  C07K2319/33

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.

公开(公告)号：US11999794B2

公开(公告)日：2024-06-04

申请号：US16750951

申请日：2020-01-23

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Gregory Beatty ,  Boris Engels ,  Neeraja Idamakanti ,  Carl H. June ,  Andreas Loew ,  Huijuan Song ,  Qilong Wu

IPC: C07K16/30 ,  A61K31/436 ,  A61K38/00 ,  A61K38/17 ,  A61K39/00 ,  A61K39/395 ,  A61K48/00 ,  C07K14/705 ,  C07K14/715 ,  C07K14/725 ,  C12N5/0783 ,  C12N15/85 ,  C12N15/86

CPC classification number: C07K16/30 ,  A61K31/436 ,  A61K38/1774 ,  A61K38/1793 ,  A61K39/001168 ,  A61K39/39558 ,  A61K48/0058 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/7151 ,  C07K16/303 ,  C07K16/3061 ,  C07K16/3069 ,  C12N5/0638 ,  C12N15/85 ,  C12N15/86 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/5158 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/74 ,  C12N2740/15041

Abstract: Provided are compositions and methods for treating diseases associated with expression of mesothelin. Also provided are a chimeric antigen receptor (CAR) specific to mesothelin, vectors encoding the same, and recombinant T cells comprising the mesothelin CAR. Further provided are methods of administering a genetically modified T cell expressing a CAR that comprises a mesothelin binding domain.